Latest recommendation report
Valuation:$50.50Last updated:07/12/21Magellan CEO Departure Does Not Impact Group Earnings Outlook, FVE Unchanged at AUD 50.50
Investment rating
Magellan has historically delivered above market returns with relatively low drawdowns. This has allowed it to rapidly grow scale in FUM to over AUD 110 billion and provides the foundation for continued earnings growth. While we don't believe it will be immune from the structural trend of investors moving to passive investments, ongoing competition among fund managers and major institutions in-housing their asset management, we think it's better placed than most active managers to address these headwinds. Magellan is moving beyond just managing money, to implementing new initiatives such as product expansion to attract new money. There are prospects of stronger inflows, notably from Australia's self-managed superannuation funds, the ageing demographic, and fee-conscious investors who were previously discouraged from investing with Magellan. However, continued strong performance will remain key.
Event
Impact
Recommendation impact (last updated: 07/12/2021)
<br /> <br /> <br /> <br /> <br />
Event analysis
Magellan CEO Departure Does Not Impact Group Earnings Outlook, FVE Unchanged at AUD 50.50
We retain our fair value estimate on narrow-moat Magellan at AUD 50.50. We think Dr. Brett Cairns' departure has no bearing on the group's earnings outlook. Dr. Cairns assumed the role as CEO in 2019 and played a pivotal role in driving Magellan's product enhancement initiatives, notably its exchange traded products and retirement income fund, FuturePay. He is also a board member at investment bank Barrenjoey, a principal investment of Magellan's, though we understand he will be relinquishing that position as well.
We don't expect Magellan's corporate strategy to change. CFO Kirsten Morton will assume the role of interim CEO while a new CEO is found. Key person Hamish Douglass remains chairman, chief investment officer and lead portfolio manager.
The main takeaway for investors is that Dr. Cairns leaves Magellan with a product suite with strong growth prospects. It allows Magellan to capitalise on emerging investor trends--namely the need for retirement income (via FuturePay), growing allocation to passive investments (via MFG Core Series), and the popularity of environmental, social, and governance, or ESG, investing (via the Magellan Sustainable strategy). We expect these products to drive about AUD 2 billion of inflows over the medium term, and remind investors that new funds typically take around three years to build a credible track record before they attract meaningful funds under management, or FUM, flows.
With AUD 116 billion in FUM, it is the compounding of market returns that drives Magellan's earnings, not net inflows. We forecast market returns averaging 9% per year over the next five years, more than offsetting our forecast cumulative outflows from its mature retail funds of AUD 5 billion (or 4% of current FUM). We currently bake in AUD 3.5 billion of net institutional outflows from fiscal 2022-24--not large--as most of Magellan's institutional clients hire it to deliver absolute returns of 10% per year, which it soundly delivered.
Previous close Market cap $29.100 $5,404 Million 52 week high/low $58.520 - $28.660 Sector Diversified Financials
Intrinsic valuation
Moat rating Narrow Business risk Medium Pricing risk -- Company beta 0.71 Sector beta 1.23
Year 06/20A 06/21A 06/22E 06/23E NPAT ($m) 438.3 412.7 489.2 513.2 EPS (c) 241.5 225.0 266.2 279.2 % change 17.2 -6.8 18.3 4.9 DPS (c) 214.9 211.2 234.0 240.6 Franking (%) 75.0 75.0 75.0 75.0 Yield (%) 3.9 3.9 8.0 8.3 PER (x) 22.6 23.9 10.9 10.4 Source: Aspect Huntley analyst estimates.
6 month price chart
- Forums
- ASX - By Stock
- MFG
- MFG in the BUY zone
MFG
magellan financial group limited
Add to My Watchlist
0.00%
!
$8.49

MFG in the BUY zone, page-913
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$8.49 |
Change
0.000(0.00%) |
Mkt cap ! $1.461B |
Open | High | Low | Value | Volume |
$8.50 | $8.67 | $8.48 | $3.088M | 361.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1950 | $8.48 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$8.59 | 5048 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1950 | 8.480 |
4 | 10603 | 8.300 |
1 | 1175 | 8.200 |
1 | 1124 | 8.150 |
1 | 1242 | 8.050 |
Price($) | Vol. | No. |
---|---|---|
8.590 | 5048 | 2 |
8.600 | 3116 | 4 |
8.610 | 1950 | 1 |
8.630 | 2950 | 2 |
8.650 | 3409 | 2 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
MFG (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online